NTI
NEUROTECH INTERNATIONAL LIMITED
$0.0200
0.00%
Market cap
$32M
Turnover
$105,774
Last price
$0.0200
Day change
0.00%
Announcements
11
Range, past year
Open 0.016 · Low 0.010 · Now 0.020 · High 0.029
Open NTI in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
NTI momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-11-16.
Momentum quality
44/100
Wyckoff phase
Distribution4d
Trend stage
Emerging
1 Day
+0.0%
1 Week
+25.0%
1 Month
+17.6%
1 Year
+17.6%
RSI
66
Avg daily range
6.5%
NEUROTECH INTERNATIONAL LIMITED scores 44 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Emerging.
On the Wyckoff cycle it sits in Distribution, where it has been for 4 trading days. The weekly timeframe reads Uptrend, which does not yet agree with the daily view.
Against the wider market it is currently outperforming and the institutional accumulation signal reads low.
What stands out
- Fresh trend age (26 days)
- Within 4.8% of 52-week high
- RSI in healthy zone (66)
Points to watch
- High volatility (ATR 6.5%)
- Risk rating: High
- Composite downside risk elevated
Browse the whole market by signal:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highsNTI announcements
Recent price-sensitive releases.
- 2026-10-28 Quarterly Activities/Appendix 4C Cash Flow Report Commitments Test Entity - First Quarter Activity Report | Commitments Test Entity - First Quarter Cashflow Report
- 2026-09-21 NTI Doses First Patient in Phase 3 Beyond Harmony ASD Study Progress Report
- 2026-08-26 Appendix 4E & Annual Report to shareholders Annual Report | Top 20 shareholders | Preliminary Final Report | Full Year Accounts | Full Year Audit Review | Full Year Directors' Statement | Full Year Directors' Report
- 2026-08-04 Receipt of Binding Commitments for $4.5m Placement Placement | Trading Halt Lifted
- 2026-07-31 Quarterly Activities/Appendix 4C Cash Flow Report Commitments Test Entity - Fourth Quarter Activity Report | Commitments Test Entity - Fourth Quarter Cashflow Report
- 2026-07-31 Trading Halt Trading Halt
- 2026-07-15 Neurotech secures $3.15 million R&D tax incentive loan
More Health Care stocks
Most traded in the same sector.